Drug and Gene Delivery Devices Market Report and Forecast 2025-2034
Description
The global drug and gene delivery devices market was valued at USD 670.00 Million in 2024, driven by the increasing prevalence of chronic diseases and technological advancements across the globe. The market is anticipated to grow at a CAGR of 9.00% during the forecast period of 2025-2034, with the values likely to reach USD 1586.13 Million by 2034.
Drug and Gene Delivery Devices Market Overview
Drug and gene delivery devices help control the delivery of drugs or genetic material in targeted body areas, leading to improved treatment outcomes. The drug and gene delivery devices increase patient compliance and optimize drug absorption while reducing side effects. The market for drug and gene delivery devices is focusing on the technology that allows targeted delivery of therapeutic agents, ensuring proper treatment. Increasing health needs, coupled with precision medicine and biotechnology advances, are driving market growth.
Drug and Gene Delivery Devices Market Growth Drivers
Increasing Prevalence of Chronic Diseases
The increase in chronic diseases like cancer, diabetes, and cardiovascular disease has spurred the demand for more advanced drug delivery systems. The Centers for Disease Control and Prevention reported that in the United States, an estimated 129 million people have at least one major chronic disease. These diseases often demand prolonged treatment where effective targeted, and efficient delivery devices can lead to better therapeutic benefits and minimal side effects, which enhances quality of life. As the global patient population increases, the need for effective delivery devices also increases.
Technological Advancements in Biotechnology to Boost Drug and Gene Delivery Devices Market Value
Advances in biotechnology, including CRISPR and gene editing, have significantly transformed gene delivery techniques. New drug delivery systems like nanoparticles, smart polymers, and biodegradable carriers have made it possible to release therapeutic agents precisely and in a controlled manner for enhanced efficacy. Such innovation is key to the development of gene-based therapies that would otherwise be impossible, opening the potential market.
Drug and Gene Delivery Devices Market Trends
The market is witnessing several trends and developments to improve the current scenario. Some of the notable trends are as follows:
Advancements in Nanotechnology for Drug Delivery
Nanotechnology is revolutionizing the drug delivery market as it allows the development of nanoparticles and nanocarriers that target specific cells or tissues. Nano-based drug delivery systems are more precise, as drugs are directly delivered to the disease site with minimal damage to healthy tissues. This ensures better efficacy of treatment with reduced side effects, thereby driving the adoption of this technology.
Growing Adoption of Needle-Free Drug Delivery Devices
Needle-free drug delivery systems such as transdermal patches and oral drug formulations find increasing acceptability because of being pain-free with ease of application. Such devices reduce the fear and discomfort associated with traditional injection-based needle technology in chronic disease management. It is shaping drug delivery by generating increased patient comfort and adherence to treatment regimens.
Rise of 3D-Printed Drug Delivery Systems to Meet Growing Drug and Gene Delivery Devices Market Demand
3D printing is revolutionizing drug delivery device design and manufacturing highly customizable forms. The development of personalized formulations, exact dosages, and appropriate delivery mechanisms by 3D printing technology makes these systems more flexible, efficient, and cost-effective to produce innovations in personalized medicine.
Emphasis on Biocompatible and Smart Drug Delivery Devices
Biocompatible and smart drug delivery devices that interact with the body's systems to provide optimal drug release times are gaining popularity. The adoption of these devices offers real-time monitoring to ensure the administration of the drug only when necessary, improving treatment efficacy. The increasing trend for such smart systems is, therefore, an indicator of the industry's efforts in improving patient care and avoiding hospital visits.
Drug and Gene Delivery Devices Market Segmentation
The market report offers a detailed analysis of the market based on the following segments:
Market Breakup by Delivery Type
Segmentation Based on Route of Administration to Witness Substantial Growth
Based on route of administration, the market is segmented into oral, injectable, ocular, inhalation, nasal, transdermal, and topical. Among these, the injectable segment is expected to represent a significant share of the market. This is based on the high demand for injectable devices, especially for biologics and vaccines, which involve precise, controlled delivery to ensure the effectiveness of the drug. Apart from this, injectables also play a crucial role in chronic disease treatment and cancer therapy, which makes them dominant.
Drug and Gene Delivery Devices Market Analysis by Region
The market is divided into regions such as North America, Europe, Asia Pacific, Latin America, and the Middle East and Africa. North America holds a large market share, mainly attributed to the strong healthcare structure, huge demand for better treatment options, and extensive investments in biotechnology and pharmaceuticals. The region's regulatory environment also propels innovation, which means that new drug delivery devices can quickly be commercialized. There is also an enormous patient population suffering from chronic diseases and genetic disorders, which catalyzes the growth of the market.
Leading Players in the Drug and Gene Delivery Devices Market
The key features of the market report comprise patent analysis, funding and investment analysis, and strategic initiatives by the leading players. The major companies in the market are as follows:
Shanghai Sunway Biotech Co., Ltd
Shanghai Sunway Biotech contributes significantly to the market with advancements in gene therapy and immunotherapy solutions. Its GMP-certified oncolytic adenovirus production lines, combined with its manufacturing plasmids and viruses help to fill the increased demand for novel gene therapies and drug delivery systems, thereby expanding the market.
Pfizer, Inc.
Pfizer is headquartered in New York, USA, and was established in 1849. It is one of the world's largest biopharmaceutical and drug delivery technologies, with key contributions to the gene delivery market. Notable products include its mRNA-based COVID-19 vaccines co-developed with BioNTech, as well as its groundbreaking partnership with Zipline to boost medicine delivery by drones in underprivileged areas.
Novartis AG
Novartis has its headquarters in Basel, Switzerland, and was established in 1996. It is the global leader in gene and drug delivery technologies, mainly focusing on AAV-based therapies as well as CRISPR-based technologies. Some of its leading products are gene therapies for spinal muscular atrophy and other treatments for potential neurological and ophthalmological disorders.
Bayer AG
Bayer AG is a German company from Leverkusen, founded in 1863. As a well-known leader in healthcare services, it specializes in modern cell and gene therapy options. Its key offerings to the gene delivery market encompass gene therapies for inherited diseases and acquired diseases, cellular therapies for damaged or otherwise malfunctioning cells, and genome editing tools.
Other key players in the market include Uniqure N.V., SiBiono GeneTech Co., Epeius Biotechnologies Corporation, F. Hoffmann-La Roche Ltd., and Becton, Dickinson and Company.
Key Questions Answered in the Drug and Gene Delivery Devices Market Report
Drug and Gene Delivery Devices Market Overview
Drug and gene delivery devices help control the delivery of drugs or genetic material in targeted body areas, leading to improved treatment outcomes. The drug and gene delivery devices increase patient compliance and optimize drug absorption while reducing side effects. The market for drug and gene delivery devices is focusing on the technology that allows targeted delivery of therapeutic agents, ensuring proper treatment. Increasing health needs, coupled with precision medicine and biotechnology advances, are driving market growth.
Drug and Gene Delivery Devices Market Growth Drivers
Increasing Prevalence of Chronic Diseases
The increase in chronic diseases like cancer, diabetes, and cardiovascular disease has spurred the demand for more advanced drug delivery systems. The Centers for Disease Control and Prevention reported that in the United States, an estimated 129 million people have at least one major chronic disease. These diseases often demand prolonged treatment where effective targeted, and efficient delivery devices can lead to better therapeutic benefits and minimal side effects, which enhances quality of life. As the global patient population increases, the need for effective delivery devices also increases.
Technological Advancements in Biotechnology to Boost Drug and Gene Delivery Devices Market Value
Advances in biotechnology, including CRISPR and gene editing, have significantly transformed gene delivery techniques. New drug delivery systems like nanoparticles, smart polymers, and biodegradable carriers have made it possible to release therapeutic agents precisely and in a controlled manner for enhanced efficacy. Such innovation is key to the development of gene-based therapies that would otherwise be impossible, opening the potential market.
Drug and Gene Delivery Devices Market Trends
The market is witnessing several trends and developments to improve the current scenario. Some of the notable trends are as follows:
Advancements in Nanotechnology for Drug Delivery
Nanotechnology is revolutionizing the drug delivery market as it allows the development of nanoparticles and nanocarriers that target specific cells or tissues. Nano-based drug delivery systems are more precise, as drugs are directly delivered to the disease site with minimal damage to healthy tissues. This ensures better efficacy of treatment with reduced side effects, thereby driving the adoption of this technology.
Growing Adoption of Needle-Free Drug Delivery Devices
Needle-free drug delivery systems such as transdermal patches and oral drug formulations find increasing acceptability because of being pain-free with ease of application. Such devices reduce the fear and discomfort associated with traditional injection-based needle technology in chronic disease management. It is shaping drug delivery by generating increased patient comfort and adherence to treatment regimens.
Rise of 3D-Printed Drug Delivery Systems to Meet Growing Drug and Gene Delivery Devices Market Demand
3D printing is revolutionizing drug delivery device design and manufacturing highly customizable forms. The development of personalized formulations, exact dosages, and appropriate delivery mechanisms by 3D printing technology makes these systems more flexible, efficient, and cost-effective to produce innovations in personalized medicine.
Emphasis on Biocompatible and Smart Drug Delivery Devices
Biocompatible and smart drug delivery devices that interact with the body's systems to provide optimal drug release times are gaining popularity. The adoption of these devices offers real-time monitoring to ensure the administration of the drug only when necessary, improving treatment efficacy. The increasing trend for such smart systems is, therefore, an indicator of the industry's efforts in improving patient care and avoiding hospital visits.
Drug and Gene Delivery Devices Market Segmentation
The market report offers a detailed analysis of the market based on the following segments:
Market Breakup by Delivery Type
- Drug Delivery System
- Intrauterine Implants
- Prodrug Implants
- Polymeric Drug Delivery
- Targeted Drug Delivery
- Gene Delivery System
- Viral Gene Delivery Adenovirus Vector Retrovirus Vector Lentivirus Vector Retrovirus Vector Adeno Associated Virus Vector Sendai Virus Vector Herpes Simplex Virus Others
- Non-Viral Gene Delivery Natural Organic Compound Physical Method Chemical Method
- Combined Hybrid Method
- Oral
- Injectable
- Inhalation
- Transdermal
- Ocular
- Nasal
- Topical
- Infectious Disease
- Oncology
- Ophthalmology
- Urology
- Diabetes
- CNC
- Others
- North America
- Europe
- Asia Pacific
- Latin America
- Middle East and Africa
Segmentation Based on Route of Administration to Witness Substantial Growth
Based on route of administration, the market is segmented into oral, injectable, ocular, inhalation, nasal, transdermal, and topical. Among these, the injectable segment is expected to represent a significant share of the market. This is based on the high demand for injectable devices, especially for biologics and vaccines, which involve precise, controlled delivery to ensure the effectiveness of the drug. Apart from this, injectables also play a crucial role in chronic disease treatment and cancer therapy, which makes them dominant.
Drug and Gene Delivery Devices Market Analysis by Region
The market is divided into regions such as North America, Europe, Asia Pacific, Latin America, and the Middle East and Africa. North America holds a large market share, mainly attributed to the strong healthcare structure, huge demand for better treatment options, and extensive investments in biotechnology and pharmaceuticals. The region's regulatory environment also propels innovation, which means that new drug delivery devices can quickly be commercialized. There is also an enormous patient population suffering from chronic diseases and genetic disorders, which catalyzes the growth of the market.
Leading Players in the Drug and Gene Delivery Devices Market
The key features of the market report comprise patent analysis, funding and investment analysis, and strategic initiatives by the leading players. The major companies in the market are as follows:
Shanghai Sunway Biotech Co., Ltd
Shanghai Sunway Biotech contributes significantly to the market with advancements in gene therapy and immunotherapy solutions. Its GMP-certified oncolytic adenovirus production lines, combined with its manufacturing plasmids and viruses help to fill the increased demand for novel gene therapies and drug delivery systems, thereby expanding the market.
Pfizer, Inc.
Pfizer is headquartered in New York, USA, and was established in 1849. It is one of the world's largest biopharmaceutical and drug delivery technologies, with key contributions to the gene delivery market. Notable products include its mRNA-based COVID-19 vaccines co-developed with BioNTech, as well as its groundbreaking partnership with Zipline to boost medicine delivery by drones in underprivileged areas.
Novartis AG
Novartis has its headquarters in Basel, Switzerland, and was established in 1996. It is the global leader in gene and drug delivery technologies, mainly focusing on AAV-based therapies as well as CRISPR-based technologies. Some of its leading products are gene therapies for spinal muscular atrophy and other treatments for potential neurological and ophthalmological disorders.
Bayer AG
Bayer AG is a German company from Leverkusen, founded in 1863. As a well-known leader in healthcare services, it specializes in modern cell and gene therapy options. Its key offerings to the gene delivery market encompass gene therapies for inherited diseases and acquired diseases, cellular therapies for damaged or otherwise malfunctioning cells, and genome editing tools.
Other key players in the market include Uniqure N.V., SiBiono GeneTech Co., Epeius Biotechnologies Corporation, F. Hoffmann-La Roche Ltd., and Becton, Dickinson and Company.
Key Questions Answered in the Drug and Gene Delivery Devices Market Report
- What was the drug and gene delivery devices market value in 2024?
- What is the drug and gene delivery devices market forecast outlook for 2025-2034?
- What are the regional markets covered in the EMR report?
- What is the market segmentation based on delivery system?
- What is the market segmentation based on route of administration?
- What is the market breakup based on the application?
- What major factors aid the drug and gene delivery devices market demand?
- How has the market performed so far and how is it anticipated to perform in the coming years?
- What are the major drivers, opportunities, and restraints in the market?
- What are the major trends influencing the market?
- Which regional market is expected to dominate the market share in the forecast period?
- Which country is likely to experience elevated growth during the forecast period?
- Who are the key players involved in the drug and gene delivery devices market?
- What are the current unmet needs and challenges in the market?
- How are partnerships, collaborations, mergers, and acquisitions among the key market players shaping the market dynamics?
Table of Contents
400 Pages
- 1 Preface
- 1.1 Objectives of the Study
- 1.2 Key Assumptions
- 1.3 Report Coverage – Key Segmentation and Scope
- 1.4 Research Methodology
- 2 Executive Summary
- 3 Global Drug and Gene Delivery Devices Market Overview
- 3.1 Global Drug and Gene Delivery Devices Market Historical Value (2018-2024)
- 3.2 Global Drug and Gene Delivery Devices Market Forecast Value (2025-2034)
- 4 Vendor Positioning Analysis
- 4.1 Key Vendors
- 4.2 Prospective Leaders
- 4.3 Niche Leaders
- 4.4 Disruptors
- 5 Global Drug and Gene Delivery Devices Market Landscape*
- 5.1 Global Drug and Gene Delivery Devices Market: Developers Landscape
- 5.1.1 Analysis by Year of Establishment
- 5.1.2 Analysis by Company Size
- 5.1.3 Analysis by Region
- 5.2 Global Drug and Gene Delivery Devices Market: Product Landscape
- 5.2.1 Analysis by Delivery System
- 5.2.2 Analysis by Route of Administration
- 6 Global Drug and Gene Delivery Devices Market Dynamics
- 6.1 Market Drivers and Constraints
- 6.2 SWOT Analysis
- 6.2.1 Strengths
- 6.2.2 Weaknesses
- 6.2.3 Opportunities
- 6.2.4 Threats
- 6.3 PESTEL Analysis
- 6.3.1 Political
- 6.3.2 Economic
- 6.3.3 Social
- 6.3.4 Technological
- 6.3.5 Legal
- 6.3.6 Environment
- 6.4 Porter’s Five Forces Model
- 6.4.1 Bargaining Power of Suppliers
- 6.4.2 Bargaining Power of Buyers
- 6.4.3 Threat of New Entrants
- 6.4.4 Threat of Substitutes
- 6.4.5 Degree of Rivalry
- 6.5 Key Demand Indicators
- 6.6 Key Price Indicators
- 6.7 Industry Events, Initiatives, and Trends
- 6.8 Value Chain Analysis
- 7 Global Drug and Gene Delivery Devices Market Segmentation (218-2034)
- 7.1 Global Drug and Gene Delivery Devices Market (2018-2034) by Delivery System
- 7.1.1 Market Overview
- 7.1.2 Drug Delivery System
- 7.1.2.1 Intrauterine Implants
- 7.1.2.2 Prodrug Implants
- 7.1.2.3 Polymeric Drug Delivery
- 7.1.2.4 Targeted Drug Delivery
- 7.1.3 Gene Delivery System
- 7.1.3.1 Viral Gene Delivery
- 7.1.3.1.1 Adenovirus Vector
- 7.1.3.1.2 Retrovirus Vector
- 7.1.3.1.3 Lentivirus Vector
- 7.1.3.1.4 Adeno Associated Virus Vector
- 7.1.3.1.5 Sendai Virus Vector
- 7.1.3.1.6 Herpes Simplex Virus
- 7.1.3.1.7 Others
- 7.1.3.2 Non-Viral Gene Delivery
- 7.1.3.2.1 Natural Organic Compound
- 7.1.3.2.2 Physical Method
- 7.1.3.2.3 Chemical Method
- 7.1.3.3 Combined Hybrid Method
- 7.2 Global Drug and Gene Delivery Devices Market (2018-2034) by Route of Administration
- 7.2.1 Market Overview
- 7.2.2 Oral
- 7.2.3 Injectable
- 7.2.4 Inhalation
- 7.2.5 Transdermal
- 7.2.6 Ocular
- 7.2.7 Nasal
- 7.2.8 Topical
- 7.3 Global Drug and Gene Delivery Devices Market (2018-2034) by Application
- 7.3.1 Market Overview
- 7.3.2 Infectious Disease
- 7.3.3 Oncology
- 7.3.4 Ophthalmology
- 7.3.5 Urology
- 7.3.6 Diabetes
- 7.3.7 CNC
- 7.3.8 Others
- 7.4 Global Drug and Gene Delivery Devices Market (2018-2034) by Region
- 7.4.1 Market Overview
- 7.4.2 North America
- 7.4.3 Europe
- 7.4.4 Asia Pacific
- 7.4.5 Latin America
- 7.4.6 Middle East and Africa
- 8 North America Drug and Gene Delivery Devices Market (218-2034)
- 8.1 North America Drug and Gene Delivery Devices Market (2018-2034) by Delivery System
- 8.1.1 Market Overview
- 8.1.2 Drug Delivery System
- 8.1.2.1 Intrauterine Implants
- 8.1.2.2 Prodrug Implants
- 8.1.2.3 Polymeric Drug Delivery
- 8.1.2.4 Targeted Drug Delivery
- 8.1.3 Gene Delivery System
- 8.1.3.1 Viral Gene Delivery
- 8.1.3.1.1 Adenovirus Vector
- 8.1.3.1.2 Retrovirus Vector
- 8.1.3.1.3 Lentivirus Vector
- 8.1.3.1.4 Adeno Associated Virus Vector
- 8.1.3.1.5 Sendai Virus Vector
- 8.1.3.1.6 Herpes Simplex Virus
- 8.1.3.1.7 Others
- 8.1.3.2 Non-Viral Gene Delivery
- 8.1.3.2.1 Natural Organic Compound
- 8.1.3.2.2 Physical Method
- 8.1.3.2.3 Chemical Method
- 8.1.3.3 Combined Hybrid Method
- 8.2 North America Drug and Gene Delivery Devices Market (2018-2034) by Route of Administration
- 8.2.1 Market Overview
- 8.2.2 Oral
- 8.2.3 Injectable
- 8.2.4 Inhalation
- 8.2.5 Transdermal
- 8.2.6 Ocular
- 8.2.7 Nasal
- 8.2.8 Topical
- 8.3 North America Drug and Gene Delivery Devices Market (2018-2034) by Application
- 8.3.1 Market Overview
- 8.3.2 Infectious Disease
- 8.3.3 Oncology
- 8.3.4 Ophthalmology
- 8.3.5 Urology
- 8.3.6 Diabetes
- 8.3.7 CNC
- 8.3.8 Others
- 8.4 North America Drug and Gene Delivery Devices Market (2018-2034) by Country
- 8.4.1 United States of America
- 8.4.1.1 United States of America Drug and Gene Delivery Devices Market (2018-2034) by Delivery System
- 8.4.2 Canada
- 8.4.2.1 Canada Drug and Gene Delivery Devices Market (2018-2034) by Delivery System
- 9 Europe Drug and Gene Delivery Devices Market (218-2034)
- 9.1 Europe Drug and Gene Delivery Devices Market (2018-2034) by Delivery System
- 9.1.1 Market Overview
- 9.1.2 Drug Delivery System
- 9.1.2.1 Intrauterine Implants
- 9.1.2.2 Prodrug Implants
- 9.1.2.3 Polymeric Drug Delivery
- 9.1.2.4 Targeted Drug Delivery
- 9.1.3 Gene Delivery System
- 9.1.3.1 Viral Gene Delivery
- 9.1.3.1.1 Adenovirus Vector
- 9.1.3.1.2 Retrovirus Vector
- 9.1.3.1.3 Lentivirus Vector
- 9.1.3.1.4 Adeno Associated Virus Vector
- 9.1.3.1.5 Sendai Virus Vector
- 9.1.3.1.6 Herpes Simplex Virus
- 9.1.3.1.7 Others
- 9.1.3.2 Non-Viral Gene Delivery
- 9.1.3.2.1 Natural Organic Compound
- 9.1.3.2.2 Physical Method
- 9.1.3.2.3 Chemical Method
- 9.1.3.3 Combined Hybrid Method
- 9.2 Europe Drug and Gene Delivery Devices Market (2018-2034) by Route of Administration
- 9.2.1 Market Overview
- 9.2.2 Oral
- 9.2.3 Injectable
- 9.2.4 Inhalation
- 9.2.5 Transdermal
- 9.2.6 Ocular
- 9.2.7 Nasal
- 9.2.8 Topical
- 9.3 Europe Drug and Gene Delivery Devices Market (2018-2034) by Application
- 9.3.1 Market Overview
- 9.3.2 Infectious Disease
- 9.3.3 Oncology
- 9.3.4 Ophthalmology
- 9.3.5 Urology
- 9.3.6 Diabetes
- 9.3.7 CNC
- 9.3.8 Others
- 9.4 Europe Drug and Gene Delivery Devices Market (2018-2034) by Country
- 9.4.1 United Kingdom
- 9.4.1.1 United Kingdom Drug and Gene Delivery Devices Market Size (2018-2034) by Delivery System
- 9.4.2 Germany
- 9.4.2.1 Germany Drug and Gene Delivery Devices Market Size (2018-2034) by Delivery System
- 9.4.3 France
- 9.4.3.1 France Drug and Gene Delivery Devices Market (2018-2034) by Delivery System
- 9.4.4 Italy
- 9.4.4.1 Italy Drug and Gene Delivery Devices Market (2018-2034) by Delivery System
- 9.4.5 Others
- 10 Asia Pacific Drug and Gene Delivery Devices Market (218-2034)
- 10.1 Asia Pacific Drug and Gene Delivery Devices Market (2018-2034) by Delivery System
- 10.1.1 Market Overview
- 10.1.2 Drug Delivery System
- 10.1.2.1 Intrauterine Implants
- 10.1.2.2 Prodrug Implants
- 10.1.2.3 Polymeric Drug Delivery
- 10.1.2.4 Targeted Drug Delivery
- 10.1.3 Gene Delivery System
- 10.1.3.1 Viral Gene Delivery
- 10.1.3.1.1 Adenovirus Vector
- 10.1.3.1.2 Retrovirus Vector
- 10.1.3.1.3 Lentivirus Vector
- 10.1.3.1.4 Adeno Associated Virus Vector
- 10.1.3.1.5 Sendai Virus Vector
- 10.1.3.1.6 Herpes Simplex Virus
- 10.1.3.1.7 Others
- 10.1.3.2 Non-Viral Gene Delivery
- 10.1.3.2.1 Natural Organic Compound
- 10.1.3.2.2 Physical Method
- 10.1.3.2.3 Chemical Method
- 10.1.3.3 Combined Hybrid Method
- 10.2 Asia Pacific Drug and Gene Delivery Devices Market (2018-2034) by Route of Administration
- 10.2.1 Market Overview
- 10.2.2 Oral
- 10.2.3 Injectable
- 10.2.4 Inhalation
- 10.2.5 Transdermal
- 10.2.6 Ocular
- 10.2.7 Nasal
- 10.2.8 Topical
- 10.3 Asia Pacific Drug and Gene Delivery Devices Market (2018-2034) by Application
- 10.3.1 Market Overview
- 10.3.2 Infectious Disease
- 10.3.3 Oncology
- 10.3.4 Ophthalmology
- 10.3.5 Urology
- 10.3.6 Diabetes
- 10.3.7 CNC
- 10.3.8 Others
- 10.4 Asia Pacific Drug and Gene Delivery Devices Market (2018-2034) by Country
- 10.4.1 China
- 10.4.1.1 China Drug and Gene Delivery Devices Market (2018-2034) by Delivery System
- 10.4.2 Japan
- 10.4.2.1 Japan Drug and Gene Delivery Devices Market (2018-2034) by Delivery System
- 10.4.3 India
- 10.4.3.1 India Drug and Gene Delivery Devices Market (2018-2034) by Delivery System
- 10.4.4 ASEAN
- 10.4.4.1 ASEAN Drug and Gene Delivery Devices Market (2018-2034) by Delivery System
- 10.4.5 Australia
- 10.4.5.1 Australia Drug and Gene Delivery Devices Market (2018-2034) by Delivery System
- 10.4.6 Others
- 11 Latin America Drug and Gene Delivery Devices Market (218-2034)
- 11.1 Latin America Drug and Gene Delivery Devices Market (2018-2034) by Delivery System
- 11.1.1 Market Overview
- 11.1.2 Drug Delivery System
- 11.1.2.1 Intrauterine Implants
- 11.1.2.2 Prodrug Implants
- 11.1.2.3 Polymeric Drug Delivery
- 11.1.2.4 Targeted Drug Delivery
- 11.1.3 Gene Delivery System
- 11.1.3.1 Viral Gene Delivery
- 11.1.3.1.1 Adenovirus Vector
- 11.1.3.1.2 Retrovirus Vector
- 11.1.3.1.3 Lentivirus Vector
- 11.1.3.1.4 Adeno Associated Virus Vector
- 11.1.3.1.5 Sendai Virus Vector
- 11.1.3.1.6 Herpes Simplex Virus
- 11.1.3.1.7 Others
- 11.1.3.2 Non-Viral Gene Delivery
- 11.1.3.2.1 Natural Organic Compound
- 11.1.3.2.2 Physical Method
- 11.1.3.2.3 Chemical Method
- 11.1.3.3 Combined Hybrid Method
- 11.2 Latin America Drug and Gene Delivery Devices Market (2018-2034) by Route of Administration
- 11.2.1 Market Overview
- 11.2.2 Oral
- 11.2.3 Injectable
- 11.2.4 Inhalation
- 11.2.5 Transdermal
- 11.2.6 Ocular
- 11.2.7 Nasal
- 11.2.8 Topical
- 11.3 Latin America Drug and Gene Delivery Devices Market (2018-2034) by Application
- 11.3.1 Market Overview
- 11.3.2 Infectious Disease
- 11.3.3 Oncology
- 11.3.4 Ophthalmology
- 11.3.5 Urology
- 11.3.6 Diabetes
- 11.3.7 CNC
- 11.3.8 Others
- 11.4 Latin America Drug and Gene Delivery Devices Market (2018-2034) by Country
- 11.4.1 Brazil
- 11.4.1.1 Brazil Drug and Gene Delivery Devices Market (2018-2034) by Delivery System
- 11.4.2 Argentina
- 11.4.2.1 Argentina Drug and Gene Delivery Devices Market Size (2018-2034) by Delivery System
- 11.4.3 Mexico
- 11.4.3.1 Mexico Drug and Gene Delivery Devices Market (2018-2034) by Delivery System
- 11.4.4 Others
- 12 Middle East and Africa Drug And Gene Delivery Devices Market (218-2034)
- 12.1 Middle East and Africa Drug And Gene Delivery Devices Market (2018-2034) by Delivery System
- 12.1.1 Market Overview
- 12.1.2 Drug Delivery System
- 12.1.2.1 Intrauterine Implants
- 12.1.2.2 Prodrug Implants
- 12.1.2.3 Polymeric Drug Delivery
- 12.1.2.4 Targeted Drug Delivery
- 12.1.3 Gene Delivery System
- 12.1.3.1 Viral Gene Delivery
- 12.1.3.1.1 Adenovirus Vector
- 12.1.3.1.2 Retrovirus Vector
- 12.1.3.1.3 Lentivirus Vector
- 12.1.3.1.4 Adeno Associated Virus Vector
- 12.1.3.1.5 Sendai Virus Vector
- 12.1.3.1.6 Herpes Simplex Virus
- 12.1.3.1.7 Others
- 12.1.3.2 Non-Viral Gene Delivery
- 12.1.3.2.1 Natural Organic Compound
- 12.1.3.2.2 Physical Method
- 12.1.3.2.3 Chemical Method
- 12.1.3.3 Combined Hybrid Method
- 12.2 Middle East and Africa Drug And Gene Delivery Devices Market (2018-2034) by Route of Administration
- 12.2.1 Market Overview
- 12.2.2 Oral
- 12.2.3 Injectable
- 12.2.4 Inhalation
- 12.2.5 Transdermal
- 12.2.6 Ocular
- 12.2.7 Nasal
- 12.2.8 Topical
- 12.3 Middle East and Africa Drug And Gene Delivery Devices Market (2018-2034) by Application
- 12.3.1 Market Overview
- 12.3.2 Infectious Disease
- 12.3.3 Oncology
- 12.3.4 Ophthalmology
- 12.3.5 Urology
- 12.3.6 Diabetes
- 12.3.7 CNC
- 12.3.8 Others
- 12.4 Middle East and Africa Drug And Gene Delivery Devices Market (2018-2034) by Country
- 12.4.1 Saudi Arabia
- 12.4.1.1 Saudi Arabia Drug And Gene Delivery Devices Market (2018-2034) by Delivery System
- 12.4.2 United Arab Emirates
- 12.4.2.1 United Arab Emirates Drug And Gene Delivery Devices Market (2018-2034) by Delivery System
- 12.4.3 Nigeria
- 12.4.3.1 Nigeria Drug And Gene Delivery Devices Market Size (2018-2034) by Delivery System
- 12.4.4 South Africa
- 12.4.4.1 South Africa Drug And Gene Delivery Devices Market (2018-2034) by Delivery System
- 12.4.5 Others
- 13 Patent Analysis
- 13.1 Analysis By Delivery System of Patent
- 13.2 Analysis by Publication Year
- 13.3 Analysis by Issuing Authority
- 13.4 Analysis by Patent Age
- 13.5 Analysis by CPC Analysis
- 13.6 Analysis by Patent Valuation
- 14 Funding and Investment Analysis
- 14.1 Analysis by Funding Instances
- 14.2 Analysis by Drug Class of Funding
- 14.3 Analysis by Funding Amount
- 14.4 Analysis by Leading Players
- 14.5 Analysis by Leading Investors
- 14.6 Analysis by Geography
- 15 Strategic Initiatives
- 15.1 Analysis by Partnership Instances
- 15.2 Analysis by Drug Class of Partnership
- 15.3 Analysis by Leading Players
- 15.4 Analysis by Geography
- 16 Supplier Landscape
- 16.1 Market Share Analysis, By Region (Top 5 Companies)
- 16.1.1 Market Share Analysis: Global
- 16.1.2 Market Share Analysis: North America
- 16.1.3 Market Share Analysis: Europe
- 16.1.4 Market Share Analysis: Asia Pacific
- 16.1.5 Market Share Analysis: Others
- 16.2 Uniqure N.V.
- 16.2.1 Financial Analysis
- 16.2.2 Product Portfolio
- 16.2.3 Demographic Reach and Achievements
- 16.2.4 Company News and Development
- 16.2.5 Certifications
- 16.3 SiBiono GeneTech Co.
- 16.3.1 Financial Analysis
- 16.3.2 Product Portfolio
- 16.3.3 Demographic Reach and Achievements
- 16.3.4 Company News and Development
- 16.3.5 Certifications
- 16.4 Epeius Biotechnologies Corporation
- 16.4.1 Financial Analysis
- 16.4.2 Product Portfolio
- 16.4.3 Demographic Reach and Achievements
- 16.4.4 Company News and Development
- 16.4.5 Certifications
- 16.5 Shanghai Sunway Biotech Co., Ltd
- 16.5.1 Financial Analysis
- 16.5.2 Product Portfolio
- 16.5.3 Demographic Reach and Achievements
- 16.5.4 Company News and Development
- 16.5.5 Certifications
- 16.6 Pfizer, Inc.
- 16.6.1 Financial Analysis
- 16.6.2 Product Portfolio
- 16.6.3 Demographic Reach and Achievements
- 16.6.4 Company News and Development
- 16.6.5 Certifications
- 16.7 F. Hoffmann-La Roche Ltd.
- 16.7.1 Financial Analysis
- 16.7.2 Product Portfolio
- 16.7.3 Demographic Reach and Achievements
- 16.7.4 Company News and Development
- 16.7.5 Certifications
- 16.8 Novartis AG
- 16.8.1 Financial Analysis
- 16.8.2 Product Portfolio
- 16.8.3 Demographic Reach and Achievements
- 16.8.4 Company News and Development
- 16.8.5 Certifications
- 16.9 Bayer AG
- 16.9.1 Financial Analysis
- 16.9.2 Product Portfolio
- 16.9.3 Demographic Reach and Achievements
- 16.9.4 Company News and Development
- 16.9.5 Certifications
- 16.10 Becton, Dickinson and Company
- 16.10.1 Financial Analysis
- 16.10.2 Product Portfolio
- 16.10.3 Demographic Reach and Achievements
- 16.10.4 Company News and Development
- 16.10.5 Certifications
- 17 Global Drug And Gene Delivery Devices Market – Distribution Model (Additional Insight)
- 17.1 Overview
- 17.2 Potential Distributors
- 17.3 Key Parameters for Distribution Partner Assessment
- 18 Key Opinion Leaders (KOL) Insights (Additional Insight)
Pricing
Currency Rates
Questions or Comments?
Our team has the ability to search within reports to verify it suits your needs. We can also help maximize your budget by finding sections of reports you can purchase.
